CordenPharma Confirms $500M Boulder SPPS Expansion to More Than 42,000 L Capacity by 2028, Adding 200+ Jobs and 64,000 sq ft Lab Space
CordenPharma's Boulder, Colorado expansion is now confirmed at $500 million, with the first phase coming online in 2026 and full completion in 2028. The site will add new large-scale manufacturing lines and a greenfield facility that more than doubles its solid-phase peptide synthesis (SPPS) capacity to over 42,000 liters by 2028 — positioning Boulder among the largest peptide production sites worldwide. CordenPharma Colorado leased 64,000 square feet at BioMed Realty's Flatiron Park 5505 Central — Boulder's first purpose-built speculative lab building — and will add more than 200 employees to the existing 700-person workforce. The expansion sits within CordenPharma's broader €900M+ ($1B+) global peptide platform investment that also includes a >€500M greenfield site near Basel.